

**DCAT**

# TOP Industry NEWS

***BUSY WEEK?** Here are the  
TOP INDUSTRY NEWS stories  
you might have missed, as  
selected by DCAT Editorial  
Director Patricia Van Arnum.*

## **1. [Gilead To Acquire Kite Pharma for \\$11.9 Billion](#)**

Gilead Sciences has agreed to acquire Kite Pharma, a Santa Monica, California-headquartered cell therapy company, for approximately \$11.9 billion. Kite is advancing a late-stage chimeric antigen receptor T cell (CAR-T) therapy that some have projected for near blockbuster status. [Read More](#)

## **2. [EC Continues Review of Bayer's \\$66-Billion Acquisition of Monsanto](#)**

The European Commission (EC) has initiated a Phase II investigation of Bayer's proposed \$66-billion acquisition of Monsanto, a St. Louis, Missouri-headquartered agrochemical and seed company. The companies had announced the acquisition in September 2016. [Read More](#)

## **3. [Thermo Fisher Completes \\$7.2-Billion Acquisition of Patheon](#)**

Thermo Fisher Scientific has completed its \$7.2-billion acquisition of Patheon, a CDMO of active pharmaceutical ingredients and drug products. Thermo Fisher had first announced the acquisition in May 2017. [Read More](#)

## **4. [FDA Approves First CAR-T Therapy to Novartis](#)**

The FDA has approved Novartis' cancer treatment, Kymriah (tisagenlecleucel), as the first chimeric antigen receptor T cell (CAR-T) therapy available in the US. The approval was for treating certain pediatric and young adult patients with a form of acute lymphoblastic leukemia. [Read More](#)

## **5. [Gilead Opens New Manufacturing and Packaging Site](#)**

Gilead Sciences has opened a new manufacturing and packaging site in La Verne, Southern California. The new site is set to replace existing operations at the company's facility in San Dimas, California, which manufactures, packages, and labels solid oral dosage form products. [Read More](#)

## **6. [Sanofi Completes \\$650-Million Acquisition of Protein Sciences](#)**

Sanofi has completed its acquisition of Protein Sciences, a Meriden, Connecticut-based vaccines developer and manufacturer, in a deal worth up to \$750 million (\$650 million upfront and \$100 million in future milestones). [Read More](#)

## **7. [Hikma To Increase Sterile Injectables Capacity](#)**

Hikma Pharmaceuticals, an Amman, Jordan-based pharmaceutical company, has invested \$28 million in additional capacity for injectable products at its facility in Cherry Hill, New Jersey and an additional \$8 million at its site in Terrugem, Portugal. The company plans to build a facility exclusively for injectable oncology products at its Portugal site. [Read More](#)

## **8. [FDA Sets GDUFA Fees for FY 2018](#)**

The FDA has set fiscal year (FY) 2018 rates for the Generic Drug User Fee Amendments (GDUFA) fees, which are fees for the generic drug industry that supplement costs from the FDA for reviewing applications and inspecting facilities. [Read More](#)

## **9. [BI Gets FDA OK for Biosimilar to AbbVie's Humira](#)**

The FDA has approved Boehringer Ingelheim's Cyltezo (adalimumab), a biosimilar to Abbvie's anti-inflammatory drug Humira. Humira had 2016 revenues of \$16.08 billion. This is part of *DCAT Value Chain Insights* Drug Approval News. [Read More](#)

## 10. [Biogen, Samsung Bioepis Get EU OK for Humira Biosimilar](#)

The European Commission has granted a marketing authorization to Biogen and Samsung Bioepis for Imraldi (adalimumab), a biosimilar referencing Abbvie's Humira. This is part of *DCAT Value Chain Insights* Drug Approval News. [Read More](#)

***The DCAT organization is happy to provide this service to its members each Friday. Have a great weekend!***

### **About Top Industry News**

The DCAT organization recognizes its members have minimal time to keep up with the continuous flow of news covering this dynamic industry. To help ensure our members never miss the most important stories impacting the global pharmaceutical manufacturing industry, we will deliver each Friday, the week's Top Industry News, as selected by DCAT Editorial Director Patricia Van Arnum.



**The Drug, Chemical & Associated Technologies Association (DCAT)** is a not-for-profit, global business development association whose unique membership model integrates both innovator and generic drug manufacturers and suppliers of ingredients, development and manufacturing services, and related technologies. We are committed to provide programs, events and services that help our members meet their business objectives, expand their network of customers and suppliers, and gain insight into industry trends, markets, and those issues impacting pharmaceutical development and manufacturing.



One Union Street, Suite 208, Robbinsville, NJ 08691  
Local: +1.609.208.1888 · Toll Free: +1.800.640.DCAT(3228) · Fax: +1.609.208.0599  
[www.dcat.org](http://www.dcat.org)

Drug, Chemical, & Associated Technologies Association, One Union Street,  
Suite 208, Robbinsville, NJ 08691

[SafeUnsubscribe™ {recipient's email}](#)

[Forward this email](#) | [Update Profile](#) | [About our service provider](#)

Sent by [dcatnews@dcat.org](mailto:dcatnews@dcat.org)